“Reaching this milestone with SSI Mantra is another step in SS Innovations strategic market expansion
, increasing access, promoting widespread use of robotic surgery,” said Dr. Sudhir Srivastava, President and CEO, SS Innovations.
“The innovative design of SSI Mantra, with the capability of a fifth arm, uniquely makes it capable of performing complex cardiac surgeries
- Demand marquee without already effective robotic solutions. Cardiac surgery often requires a maximally invasive approach that involves dividing the patient's sternum to gain access,” he said.
The advanced SSI Mantra system, used in more than 1,000 procedures globally, has completely integrated the SSI Mantra system into procedures such as Totally Endoscopic Coronary Artery Bypass (TECAB), Internal Mammary Artery (IMA) Takedown, Mitral Valve Replacement and Bilateral Internal Mammary Artery (BIMA) Takedown. has been executed successfully. ,
The system aims for “precise execution, less trauma, less blood loss, quicker recovery, and lower costs and better overall outcomes,” Dr. Srivastava said, adding that the company is expecting US FDA and CE mark approval in Europe in early 2025. Is.
According to ResearchandMarkets, the global surgical robotics market size was valued at $78.8 billion in 2022 and is projected to reach $188.8 billion by 2032, growing at a CAGR of 9.1 percent from 2023 to 2032.
, increasing access, promoting widespread use of robotic surgery,” said Dr. Sudhir Srivastava, President and CEO, SS Innovations.
“The innovative design of SSI Mantra, with the capability of a fifth arm, uniquely makes it capable of performing complex cardiac surgeries
- Demand marquee without already effective robotic solutions. Cardiac surgery often requires a maximally invasive approach that involves dividing the patient's sternum to gain access,” he said.
The advanced SSI Mantra system, used in more than 1,000 procedures globally, has completely integrated the SSI Mantra system into procedures such as Totally Endoscopic Coronary Artery Bypass (TECAB), Internal Mammary Artery (IMA) Takedown, Mitral Valve Replacement and Bilateral Internal Mammary Artery (BIMA) Takedown. has been executed successfully. ,
The system aims for “precise execution, less trauma, less blood loss, quicker recovery, and lower costs and better overall outcomes,” Dr. Srivastava said, adding that the company is expecting US FDA and CE mark approval in Europe in early 2025. Is.
According to ResearchandMarkets, the global surgical robotics market size was valued at $78.8 billion in 2022 and is projected to reach $188.8 billion by 2032, growing at a CAGR of 9.1 percent from 2023 to 2032.
